RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
Add like
Add dislike
Add to saved papers

Phospholipase A2-induced electrophysiologic and histologic changes in rabbit dorsal lumbar spine tissues.

Spine 1995 December 16
STUDY DESIGN: The present study was designed to characterize the effect of phospholipase A2 on the discharge of perispinal sensory nerves in the anesthetized New Zealand white rabbit.

OBJECTIVES: To examine the effects of phospholipase A2 on the neural response of somatosensory neurons innervating the lumbar facet joint and surrounding tissues.

SUMMARY OF BACKGROUND DATA: An irritating component of disc tissue may be phospholipase A2, which has been found at extraordinary high levels in herniated and painful discs. Phospholipase A2 has been shown to be inflammatory, but its effect on nerve response has never been shown.

METHODS: Surgically isolated facet joint capsules from rabbits were investigated by means of electrophysiologic and histologic techniques. Phospholipase A2 was injected into the characterized nerve receptive field, and responses were evaluated over time with varying doses.

RESULTS: The injection of phospholipase A2 into the nerve receptive fields produced neurotoxicity with a 1500-U dose, sensitization of the nerves and recruitment of "silent units" with a 750-U dose, and no electrophysiologic effect with a 400-U dose. The tissues injected with phospholipase A2 and control solutions were examined histologically using a hematoxylin and eosin staining technique. In all three doses, the inflammatory changes were observed as soon as 2 hours after the injections. In control subjects, no changes were observed.

CONCLUSIONS: After phospholipase A2 injection, the discharge rate of the units showed dose and time dependent patterns. Regardless of the different doses, histologic changes were observed as soon as 2 hours after the phospholipase A2 injections.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app